Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Madison, Alabama 35758


Purpose:

This study answers a U.S. Food and Drug Administration requirement for evaluation in people of a manufacturing lot of vaccine. Subjects receive one dose of one lot of vaccine. The antibodies in the blood measure the immunogenicity of the vaccine, and typical vaccine safety information is also collected.


Criteria:

Inclusion Criteria: - 8 wk of hemodialysis for ESRD, - have written informed consent, - a negative serum pregnancy test if appropriate, - and expect to comply with protocol procedures and schedule Exclusion Criteria: - known HIV, - immunomodulatory drugs, - malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early stage prostate cancer), - active infection in the 2 weeks prior to study injection, - serious S. aureus infection within the last 3 months prior to injection, - use of investigational drugs, vaccines or devices within the prior 30 days, - hypersensitivity to components of StaphVAX


NCT ID:

NCT00211900


Primary Contact:

Study Director
Matt Hohenboken, MD, PhD
Nabi Biopharmaceuticals


Backup Contact:

N/A


Location Contact:

Madison, Alabama 35758
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.